Share Email Print
cover

Proceedings Paper

Developing a sensitiser from laboratory to a clinical formulation
Author(s): Alexander D. Cross
Format Member Price Non-Member Price
PDF $14.40 $18.00

Paper Abstract

Numerous photoactivatable dyes have been proposed as photodynamic therapy (PDT) candidates during the past few years. Very few will ever graduate to approved drug status. Critical issues exist post-research which can be factored into the selection of suitable photosensitizers for development and substantially enhance prospects of success. Examples are provided by the novel porphycene family of synthetic dyes. Non-research factors such as patents, regulatory agencies and finance require early consideration. Porphycene photosensitizers have been designed chemically to ensure purity, avoid isomers, offer rapid metabolism, minimize phototoxicity and enhance target tissue selectivity while addressing key issues of safety, efficacy and economics in the development of a topically applied photosensitizer for dermatological disease.

Paper Details

Date Published: 31 January 1996
PDF: 3 pages
Proc. SPIE 2625, Photochemotherapy: Photodynamic Therapy and Other Modalities, (31 January 1996); doi: 10.1117/12.231010
Show Author Affiliations
Alexander D. Cross, Cytopharm, Inc. (United States)


Published in SPIE Proceedings Vol. 2625:
Photochemotherapy: Photodynamic Therapy and Other Modalities
Benjamin Ehrenberg; Giulio Jori; Johan Moan, Editor(s)

© SPIE. Terms of Use
Back to Top